Beta Bionics (NASDAQ:BBNX) Stock Price Up 3.8% – Still a Buy?

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) traded up 3.8% on Monday. The stock traded as high as $18.28 and last traded at $18.2950. 130,957 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,179,003 shares. The stock had previously closed at $17.63.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Jefferies initiated coverage of Beta Bionics with a “Buy” rating and a $30 price target, implying substantial upside from recent trading levels. The bullish view provides some support for the stock and reflects optimism about the company’s long-term commercial potential. Beta Bionics upgraded to Strong-Buy at Jefferies
• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Kaplan Fox, Glancy Prongay and others, reminded investors that November 3, 2026 is the deadline to seek lead-plaintiff status in a securities class action covering purchases from July 30, 2025 through February 24, 2026. These notices primarily solicit participation and do not establish that Beta Bionics is liable. Rosen investor deadline notice
• Negative Sentiment: The lawsuit activity is negative for investor sentiment because plaintiffs allege Beta Bionics misled investors about the iLet system’s safety, efficacy and commercial performance. One complaint alleges the company’s SEC disclosures characterized FDA findings as quality-system “non-conformities” while omitting hundreds of unreported iLet complaints involving potentially life-threatening hypoglycemia. The legal campaign follows a reported stock decline of more than 37% after revelations concerning FDA compliance and device safety. The allegations remain unproven, but the litigation creates regulatory, reputational and potential financial risks. BBNX medical-device safety lawsuit report

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BBNX shares. Barclays began coverage on Beta Bionics in a research report on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 target price on the stock. Robert W. Baird boosted their price objective on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Leerink Partners boosted their price objective on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Finally, UBS Group reiterated a “buy” rating and set a $25.00 target price on shares of Beta Bionics in a research report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Beta Bionics Stock Down 1.0%

The firm has a fifty day moving average of $18.91 and a two-hundred day moving average of $15.10.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The business had revenue of $32.01 million during the quarter. On average, research analysts anticipate that Beta Bionics, Inc. will post -2.02 EPS for the current fiscal year.

Insider Activity at Beta Bionics

In other news, insider Mark Hopman sold 30,779 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the completion of the transaction, the insider owned 56,479 shares in the company, valued at $1,136,922.27. This trade represents a 35.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 2,650 shares of Beta Bionics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the transaction, the insider owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. The trade was a 1.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 97,697 shares of company stock valued at $1,907,034 in the last 90 days. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Beta Bionics

A number of institutional investors have recently modified their holdings of BBNX. BlackRock Inc. bought a new stake in shares of Beta Bionics in the second quarter worth $52,340,000. Eversept Partners LP increased its holdings in shares of Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the last quarter. Perceptive Advisors LLC increased its stake in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after purchasing an additional 240,000 shares during the last quarter. 12 West Capital Management LP acquired a new position in shares of Beta Bionics in the 4th quarter valued at about $17,520,000. Finally, Bruce & Co. Inc. bought a new stake in shares of Beta Bionics during the 1st quarter valued at about $5,518,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.